Clinical data and cell-activation potential of aPLAs*
| . | Non–cell-activating aPLAs . | Cell-activating aPLAs . |
|---|---|---|
| Total | 13 | 19 |
| APS | 13 | 18 |
| SLE | 0 | 4 |
| Thrombosis | 7 | 13 |
| Fetal loss | 6 | 10 |
| LA + aCL + β2GP1 | 3 | 8 |
| LA + aCL | 2 | 4 |
| LA + β2GP1 | 0 | 0 |
| aCL + β2GP1 | 0 | 0 |
| LA | 0 | 1 |
| aCL | 8 | 6 |
| β2GP1 | 0 | 0 |
| . | Non–cell-activating aPLAs . | Cell-activating aPLAs . |
|---|---|---|
| Total | 13 | 19 |
| APS | 13 | 18 |
| SLE | 0 | 4 |
| Thrombosis | 7 | 13 |
| Fetal loss | 6 | 10 |
| LA + aCL + β2GP1 | 3 | 8 |
| LA + aCL | 2 | 4 |
| LA + β2GP1 | 0 | 0 |
| aCL + β2GP1 | 0 | 0 |
| LA | 0 | 1 |
| aCL | 8 | 6 |
| β2GP1 | 0 | 0 |
aPLA indicates antiphospholipid antibody; SLE, systemic lupus erythematosus; LA, lupus anticoagulant; aCL, anti-cardiolipin IgG; and β2GP1, anti-β2GP1 IgG.
There was no significant association between cell-activation potential and patient characteristics or positivity in any particular aPLA assay.